Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Expands Financial Assistance Program to Underinsured Patients

NEW YORK (GenomeWeb News) – Myriad Genetics today expanded its patient financial assistance program to include some who are underinsured.

Under the expanded program, Myriad will offer financial assistance to certain underinsured patients so that they have to pay out-of-pocket costs of no more than $375. To be eligible, patients must have private insurance, meet their insurers' coverage criteria for testing, and have a household income that does not exceed 200 percent of the Federal financial poverty level, Myriad said.

The expanded program covers all of the Salt Lake City firm's diagnostic tests. Myriad already offered financial assistance to uninsured patients. Those who met medical society guidelines and whose income was below 200 percent of the Federal poverty level did not have to pay Myriad for diagnostic testing.

Myriad also has been offering interest-free tailored payment programs to all patients, it said. It added that to date, it has helped more than 35,000 patients receive molecular diagnostic test through its patient financial assistance programs.

"We recognize that a large number of Americans are underinsured and have many expenses that raise their healthcare costs," Myriad President and CEO Peter Meldrum, said in a statement. "We want to ensure that those with the greatest financial need have access to our diagnostic tests and this new component of our financial assistance program will make that possible. A lack of financial resources should not be an impediment to quality healthcare."

Last month, Myriad had some of its patent claims related to its BRACAnalysis test invalidated by the US Supreme Court. Last week, it sued two firms, Ambry Genetics and Gene by Gene, alleging infringement of patent claims related to BRCA 1 and BRCA 2 genes.

The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.